Skip to content
AnalystLens

Medpace Holdings 8-K Report, Financial Results (Apr 22, 2024)

Reports
Earnings & Results·Exhibits & Filings
Filing Date
Filed April 22, 2024
Period End
April 22, 2024
Security
MEDP
In the record · 2016–202610-K1010-Q318-K90

MEDP filed 10 annual reports (10-K), 31 quarterly reports (10-Q) and 90 current reports (8-K) between 2016 and 2026.

  1. Material agreement8-K · Dec ’17Dec ’17
  2. Leadership change8-K · Mar ’20Mar ’20
  3. Material agreement8-K · Mar ’22Mar ’22
  4. Leadership change8-K · Jun ’26Jun ’26

Summary

Summary of the 8-K filed April 22, 2024. Cited figures are marked; the original filing is the authoritative source.

Medpace Holdings, Inc. (Nasdaq: MEDP) reported first quarter 2024 results on April 22, 2024, as furnished under Item 2.02 of this Form 8-K (press release attached as Exhibit 99.1).

Revenue rose 17.7% to $511.0 milliona from $434.1 million a year earlier, and backlog increased 18.2% to $2,907.1 million. Net new business awards were $615.6 million, up 10.8%, for a net book-to-bill ratio of 1.20x. Profitability improved meaningfully.

GAAP net income was $102.6 millionb, or $3.20 per diluted share, versus $72.9 million, or $2.27 per diluted share, in the prior-year quarter, with net income margin of 20.1% compared to 16.8%. EBITDA increased 24.6% to $115.7 million, a 22.6% margin. Cash and cash equivalents were $407.0 million at March 31, 2024, and operating cash flow was $152.7 million for the quarter.

No share repurchases were made in the quarter, and $308.8 millionc remained under the authorized repurchase program. For full-year 2024, the company forecasts revenue of $2.150 billion to $2.200 billion, representing growth of 14.0% to 16.7% over 2023 revenue of $1.886 billion.

GAAP net income is forecast at $347.0 million to $369.0 milliond, diluted EPS (GAAP) at $10.79 to $11.47, and EBITDA at $415.0 million to $445.0 million. The guidance assumes a 15.0% to 16.0% tax rate and 32.1 million diluted shares outstanding, and excludes any share repurchases after March 31, 2024.

Key Highlights

  1. Revenue of $511.0 million, up 17.7% from $434.1 million; constant-currency growth of 17.6%.
  2. Backlog rose 18.2% to $2,907.1 million; net new business awards of $615.6 million gave a net book-to-bill ratio of 1.20x.
  3. GAAP net income of $102.6 million, or $3.20 per diluted share, versus $2.27 per diluted share a year earlier; net income margin of 20.1% versus 16.8%.
  4. EBITDA of $115.7 million, up 24.6%, with a 22.6% margin versus 21.4% in the prior-year period.
  5. Cash and cash equivalents of $407.0 million at March 31, 2024, and operating cash flow of $152.7 million for the quarter.
  6. No share repurchases in the first quarter; $308.8 million remained under the authorized repurchase program.
  7. 2024 guidance: revenue of $2.150 billion to $2.200 billion (14.0% to 16.7% growth), GAAP net income of $347.0 million to $369.0 million, and diluted EPS of $10.79 to $11.47.

Frequently Asked Questions

  1. How did Medpace perform in the first quarter of 2024?

    Revenue grew 17.7% to $511.0 million, and GAAP net income rose to $102.6 million, or $3.20 per diluted share, from $72.9 million, or $2.27 per diluted share, a year earlier. EBITDA increased 24.6% to $115.7 million.

  2. What is the company's backlog and how strong are new awards?

    Backlog as of March 31, 2024 was $2,907.1 million, up 18.2% from $2,460.1 million a year earlier. Net new business awards were $615.6 million, up 10.8%, producing a net book-to-bill ratio of 1.20x.

  3. What full-year 2024 outlook did Medpace provide?

    The company forecasts 2024 revenue of $2.150 billion to $2.200 billion, GAAP net income of $347.0 million to $369.0 million, EBITDA of $415.0 million to $445.0 million, and diluted EPS of $10.79 to $11.47. The guidance assumes a 15.0% to 16.0% tax rate, $22.9 million of interest income, and 32.1 million diluted shares.

  4. What is the company's liquidity and capital return position?

    Cash and cash equivalents were $407.0 million at March 31, 2024, up from $245.449 million at December 31, 2023. The company generated $152.7 million in operating cash flow in the quarter, made no share repurchases, and had $308.8 million remaining under its repurchase authorization.

  5. Does the 2024 guidance include future share buybacks?

    No. The guidance does not include the potential impact of any share repurchases made under the program after March 31, 2024.